After 18 years of living with multiple myeloma, Sally Kalksma has learned that getting through cancer treatment is about more ...

Researchers are studying whether combining CAR-T cell therapy with targeted drugs could help children with high-risk leukemia, including infants whose cancer may be more likely to return after ...

In the latest installment of CURE's "Text a Survivor" series, Brad Moore answers some of the most common questions people have about living with and beyond a colorectal cancer diagnosis.

The omnipresence of pink during awareness campaigns can function as an involuntary cue for trauma recall, reactivating uncertainty, grief, and embodied memories tied to cancer care. Survivorship is ...

Researchers are studying whether combining CAR-T cell therapy with targeted drugs could help children with high-risk leukemia, including infants whose cancer may be more likely to return after ...

A partially randomized patient-preference design showed intervention receipt, not preference congruence, drove improvements in fatigue, sleep, and pain interference among distressed post-treatment ...

Progression-free survival reached 14.3 months with Enhertu versus 8.3 months with chemotherapy plus Keytruda in HER2-mutant lung cancer. In the phase 3 DESTINY-Lung04 trial, patients with HER2-mutant ...

Paxalisib blocks the PI3K/mTOR pathway, which plays a role in cancer cell growth and survival, but researchers have also ...

FDA cleared BRAVNETSA for adult SSTR+ GEP-NETs spanning foregut, midgut, and hindgut sites, adding a second approved lutetium ...

Paxalisib, first studied in brain cancer, may help HR+ breast tumors respond to CDK4/6 inhibitors again, based on early lab data.

After facing multiple cancers and hospice care, April Floyd credits her service dog Onyx with helping her find comfort, strength and hope. Years before Onyx entered my life, I lost my beloved dog ...

FDA approves Inluriyo plus Verzenio for adults with ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast ...